-
Posted by
Two Blokes May 2 -
Filed in
Stock
-
4 views
Initiate Buy on Myriad Genetics, trading near multi-year lows with potential for significant growth driven by new offerings and stable core franchises. Strong financials with $158 million in liquidity, improving margins, and a path to profitability by 2025; 2024 revenue grew 11% YoY to $838 million. Key growth drivers include GeneSight, MyRisk, Prolaris, Precise MRD, and FirstGene; significant market opportunities in psychiatric PGx, hereditary cancer, prostate prognostics, MRD, and prenatal genetics.
